Role of caveolae in the pathogenesis of cholesterol-induced gallbladder muscle hypomotility.
Muscle cells from human gallbladders (GB) with cholesterol stones (ChS) exhibit a defective contraction, excess cholesterol (Ch) in the plasma membrane, and lower binding of CCK-1 receptors. These abnormalities improved after muscle cells were incubated with Ch-free liposomes that remove the excess Ch from the plasma membrane. The present studies were designed to investigate the role of caveolin-3 proteins (Cav-3) in the pathogenesis of these abnormalities. Muscle cells from GB with ChS exhibit higher Ch levels in the plasma membrane that were mostly localized in caveolae and associated with parallel increases in the expression of Cav-3 in the caveolae compared with that in GB with pigment stones (PS). The overall number of CCK-1 receptors in the plasma membrane was not different between muscle cells from GB with ChS and PS, but they were increased in the caveolae in muscle cells from GB with ChS. Treatment of muscle cells from GB with ChS with a Galpha(i3) protein fragment increased the total binding of CCK-1 receptors (from 8.3 to 11.2%) and muscle contraction induced by CCK-8 (from 11.2 to 17.3% shortening). However, Galpha(q/11) protein fragment had no such effect. Moreover, neither fragment had any effect on muscle cells from GB with PS. We conclude that the defective contraction of muscle cells with excessive Ch levels in the plasma membrane is due to an increased expression of Cav-3 that results in the sequestration of CCK-1 receptors in the caveolae, probably by inhibiting the functions of Galpha(i3) proteins.
Xiao
Zuoliang
Z
Division of Gastroenterology, APC 406, Rhode Island Hospital/Brown Univ. Medical School, 593 Eddy St., Providence, RI 02903, USA. zuoliangxiao2000@yahoo.com
Schmitz
Frank
F
Pricolo
Victor E
VE
Biancani
Piero
P
Behar
Jose
J
D000818:Animals; D001654:Bile Pigments / Q000378:metabolism; D021941:Caveolae / Q000378:metabolism*; D051244:Caveolin 3 / Q000378:metabolism; D041761:Cholecystolithiasis / Q000378:metabolism* / Q000503:physiopathology; D002784:Cholesterol / Q000378:metabolism*; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism; D005704:Gallbladder / Q000378:metabolism* / Q000503:physiopathology; D042882:Gallstones / Q000378:metabolism*; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D008081:Liposomes / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000378:metabolism* / Q000503:physiopathology; D010446:Peptide Fragments / Q000378:metabolism; D011485:Protein Binding; D043886:Receptor, Cholecystokinin A / Q000378:metabolism; D011949:Receptors, Cholecystokinin / Q000378:metabolism; D012844:Sincalide / Q000378:metabolism
D001654:Bile Pigments; D051244:Caveolin 3; D008081:Liposomes; D010446:Peptide Fragments; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D002784:Cholesterol; C498819:GNAI3 protein, human; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D012844:Sincalide